June 4 (UPI) -- Food and Drug Administration Commissioner Marty Makary said he plans to review the safety of abortion drug mifepristone after a recent study raised concerns about medical side effects.
In a letter to Sen. Josh Hawley, R-Mo., Makary revealed the FDA's plan on Monday to review the abortion pill after Hawley alerted the commissioner to the study.
"As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the agency who review this data," Makary wrote.
"As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy," Makary added.
Related
